FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Articles|November 23, 2020
Thanksgiving 2020: COVID-19 Considerations for Patients
Author(s)Sydney Jennings
Prepare patients for a safe Thanksgiving with key CDC-based recommendations including alternative Thanksgiving activities, steps to take if exposed to COVID-19, and more.
Advertisement
As confirmed cases of
With that in mind, the US Centers for Disease Control and Prevention (CDC), recently updated its recommendations for
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5